Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

• Status: RECRUITING
• Trial end date: 2036-07-13

Summary

The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

• Phase: PHASE3

Details

• Lead Sponsor: Celgene
• Treatments: Fingolimod Hydrochloride; ozanimod